Trial Profile
An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' COPD Vaccine (GSK3277511A) in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 3277511 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms NTHI MCAT-008
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 20 Oct 2020 Status changed from active, no longer recruiting to completed.
- 27 Jul 2020 This trial has been completed in Germany.
- 10 Jun 2020 Planned End Date changed from 29 Jun 2020 to 29 Oct 2020.